Clinics I work with
My reviews
Selected research
-
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Nature communications
-
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Nature communications
Clinical trials
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
As the primary endpoint for the treatment comparison, it is the duration of time from randomization to the time of disease progression (in the CNS or systemically) or death. In addition, as a secondary endpoint, PFS is measured fr...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 885-3882
4.8